Alek Safarian, ALSA Ventures

Alek Safarian, CEO of ALSA Ventures, invests in early-stage European biotechnology companies developing novel therapeutics at. See contact routes.

About Alek Safarian

Alek Safarian, CEO of ALSA Ventures, invests in early-stage European biotechnology companies developing novel therapeutics at the preclinical proof-of-concept or early clinical development stages, with no constraints on modality or therapeutic area. The firm’s distinctive thesis leverages Safarian’s 30+ years of operational experience in pharmaceuticals and clinical research organizations (CROs) to actively guide portfolio companies through clinical development, either via syndicated deals or by forming new companies from scratch. Notable portfolio companies include UK-based Epsilogen Ltd and Oxford Biotherapeutics, Belgian startup Montis Biosciences, and ReproNovo, which received a $65M Series A in May 2025.

Alek Safarian at a glance

Role
Managing Director
Organization
ALSA Ventures
Location
London, England, United Kingdom
Investor type
Venture Capital

Frequently asked about Alek Safarian

What does Alek Safarian invest in?
We have not verified a stated sector or stage focus for Alek Safarian at ALSA Ventures (London, England, United Kingdom). The profile lists the organization, location and investors we track alongside them.
How do I contact Alek Safarian?
Alek Safarian's published profile links (website, LinkedIn or X where available) are listed on the StartupFundraising.com investor profile.
Where is Alek Safarian based?
Alek Safarian is based in London, England, United Kingdom.

Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in London.

Investors similar to Alek Safarian (20)

Browse related investor lists (2)

Compare Alek Safarian (8)

Investors like Alek Safarian · Full investor directory · Investor access · Company funding database